Codagenix initiates new study of live-attenuated vaccine in RSV

Codagenix initiates new study of live-attenuated vaccine in RSV

Source: 
Clinical Trials Arena
snippet: 

Codagenix is moving its rational virus design platform forward with a new Phase I trial of its live attenuated respiratory syncytial virus (RSV) vaccine in children.